Skip to content
lifestyle.newsblaze.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
KAZIA THERAPEUTICS LIMITED.
Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer
September 9, 2026
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
September 1, 2026
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
September 1, 2026
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer
September 1, 2026
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer
September 1, 2026
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering
September 1, 2026
Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering
August 28, 2026
Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer
August 28, 2026
Kazia Therapeutics Limited Announces Proposed Public Offering
August 28, 2026
Kazia Therapeutics Appoints James Levine as Chief Financial Officer
June 2, 2026
1
2
Next Page
→